Pantor-20/Pantor-40/Pantor IV

Tab: Short-term treatment of erosive esophagitis associated w/ GERD. Maintenance of healing erosive esophagitis & reduction in relapse rates of daytime & nighttime heartburn symptoms in adults w/ GERD. Long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome. Prophylaxis for NSAIDs-associated ulceration in patients w/ a need for continuous NSAID treatment, who have increased risk to develop NSAID-associated upper GI lesions. Eradication of H. pylori. PUD. Inj: Conditions where inhibition of gastric acid secretion may be beneficial including aspiration syndromes, dyspepsia, GERD, PUD & Zollinger-Ellison syndrome.

Pantor-20/Pantor-40 EC tab Short-term treatment of erosive esophagitis associated w/ GERD Adult 40 mg once daily up to 8 wk. An additional 8 wk for patients who have not healed after 8 wk of treatment. Childn ≥5 yr, >40 kg 40 mg, >15-<40 kg 20 mg once daily for up to 8 wk. Maintenance of healing erosive esophagitis & reduction in relapse rates of daytime & nighttime heartburn symptoms in GERD Adult 40 mg once daily. Long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome Adult 40 mg bid. Prophylaxis for NSAIDs associated ulceration Adult 20 mg once daily. Eradication of H. pylori Pantoprazole 40 mg bid w/ clarithromycin 500 mg bid & either amoxicillin 1 g bid or metronidazole 400 mg bid. PUD 40 mg once daily usually given for 2-4 wk for duodenal ulceration, or 4-8 wk for benign gastric ulceration. Hepatic impairment Max: 20 mg daily, or 40 mg on alternate days. Renal impairment Max: 40 mg. Pantor IV lyo powd for inj 1 vial/day administered over 2-15 min.

May be taken with or without food.

Hypersensitivity.

Temporary w/drawal of PPI may be considered w/ high-dose MTX administration. Caution in hepatic impairment. Should not be used during pregnancy unless clearly necessary. Discontinue breast-feeding or discontinue therapy; considering benefit of breast-feeding to the child & pantoprazole therapy to woman. Tab: Symptomatic response to therapy does not preclude the presence of gastric malignancy. Atrophic gastritis in gastric corpus biopsies from patients on long-term therapy, particularly who were H. pylori +ve. Discontinue if acute interstitial nephritis develops. Prolonged use (eg, >3 yr) may lead to malabsorption of vit B₁₂ caused by hypo- or achlorhydria. Clostridium difficile associated diarrhea. Increased risk for osteoporosis-related fractures of the hip, wrist, or spine. Monitor Mg levels prior to initiation of treatment & periodically. Inj: Malignancy should be excluded in the presence of any alarm symptoms & when gastric ulcer is suspected or present. May increase risk of subacute cutaneous lupus erythematosus (SCLE) w/ other PPIs. Consider stopping treatment if lesions occur especially in sun-exposed areas & if accompanied by arthralgia. May lead to slight increase in risk of GI infections caused by bacteria. Stop treatment for at least 5 days before chromogranin A (CgA) measurements to avoid interference. Not recommended w/ atazanavir.

Headache, diarrhea & skin rashes; pruritus, dizziness, fatigue, constipation, nausea & vomiting, flatulence, abdominal pain, arthralgia & myalgia, urticaria & dry mouth; insomnia, somnolence & vertigo.

May reduce absorption of drugs w/ gastric pH dependent bioavailability eg, some azole antifungals (ketoconazole, itraconazole, posaconazole) & other medicines eg, erlotinib. Co-administration w/ atazanavir & other HIV medications whose absorption is pH-dependent w/ PPIs might result in substantial reduction in bioavailability & impact the efficacy of HIV medications. Increased MTX levels in concomitant use w/ high dose MTX (eg, 300 mg).

Antacids, Antireflux Agents & Antiulcerants

A02BC02 - pantoprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).

Rx